The University of Texas MD Anderson Cancer Center announced it formed a research alliance with GlaxoSmithKline to strengthen its efforts in advancing therapies that train the body's immune system to combat cancer.
The collaboration completes an ambitious plan to partner with leading pharmaceutical companies to more rapidly develop cancer immunotherapies as part of MD Anderson's Moon Shots Program.
GSK and MD Anderson will work together to identify new therapeutic approaches, evaluate patient responses in clinical trials and use those insights to develop immunotherapy drugs.
MD Anderson recognized the potential of immune-based therapies by creating one of the platforms that supports its Moon Shoots Program, the institution's 10-year commitment to more rapidly develop therapies and other interventions to significantly reduce cancer deaths.
Read: more on partnering deals in pharma, biotech, life science partnering deal news, insights and glossary
Report: Practical Guide to Finding Partners
Report: Partnering Deals and Alliances with Big Pharma
Report: Partnering Deals and Alliances with Aspen Pharmacare
Report: Partnering Deals and Alliances with GlaxoSmithKline
Related reports: Bigpharma Partnering Yearbook 2013
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity